Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer’s disease

References

• Simonetti AF, Viasus D, Garcia-Vidal C, Carratalà J. Management of community-acquired pneumonia in older adults. Ther Adv Infect Dis. 2014;2:3–16.
   PubMedGoogle Scholar
• Pasqualetti G, Tognini S, Calsolaro V, Polini A, Monzani F. Potential drug-drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging. 2015;10:1457–66.
   PubMed Web of Science ®Google Scholar
• Foley NC, Affoo RH, Martin RE. A systematic review and meta-analysis examining pneumonia-associated mortality in dementia. Dement Geriatr Cogn Disord. 2015;39:52–67.
   PubMed Web of Science ®Google Scholar
• Manabe T, Teramoto S, Tamiya N, Okochi J, Hizawa N. Risk factors for aspiration pneumonia in older adults. PLoS One. 2015;10:e0140060.
   PubMed Web of Science ®Google Scholar
• Rudolph JL, Zanin NM, Jones RN, Marcantonio ER, Fong TG, Yang FM, et al. Hospitalization in community-dwelling persons with Alzheimer’s disease: frequency and causes. J Am Geriatr Soc. 2010;58:1542–8.
   PubMed Web of Science ®Google Scholar
• Lai EC, Wong MB, Iwata I, Zhang Y, Hsieh CY, Kao Yang YH, et al. Risk of pneumonia in new users of cholinesterase inhibitors for dementia. J Am Geriatr Soc. 2015;63:869–76.
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System. Structure and principles; [cited 2016 Mar 10]. Available at http://www.whocc.no/atc/structure_and_principles/.
   Google Scholar
• Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med. 2014;30:421–42.
   PubMed Web of Science ®Google Scholar
• Buckley JS, Salpeter SR. A risk-benefit assessment of dementia medications: systematic review of the evidence. Drugs Aging. 2015;32:453–67.
   PubMed Web of Science ®Google Scholar
• Rodda J, Carter J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ. 2012;344:e2986.
   PubMed Web of Science ®Google Scholar
• Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS One. 2015;10:e0123289.
   PubMed Web of Science ®Google Scholar
• Periclou A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther. 2006;79:134–43.
   PubMed Web of Science ®Google Scholar
• Finnish Medical Society Duodecim, Helsinki (2010). Current care guideline: memory disorders [in Finnish with English summary]. www.kaypahoito.fi. Date last updated: August 13 2010. Date last accessed: March 10 2015.
   Google Scholar
• Taipale H, Koponen M, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S. High prevalence of psychotropic drug use among persons with and without Alzheimer’s disease in Finnish nationwide cohort. Eur Neuropsychopharmacol. 2014;24:1729–37.
   PubMed Web of Science ®Google Scholar
• Tolppanen AM, Taipale H, Koponen M, Lavikainen P, Tanskanen A, Tiihonen J, et al. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research: the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study. Clin Epidemiol. 2013;5:277–85.
   PubMedGoogle Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology. 1984;34:939–44.
   PubMed Web of Science ®Google Scholar
• Tanskanen A, Taipale H, Koponen M, Tolppanen AM, Hartikainen S, Ahonen R, et al. From prescription drug purchases to drug use periods: a second generation method (PRE2DUP). BMC Med Inform Decis Mak. 2015;15:21-015-0140-z.
   Web of Science ®Google Scholar
• Finnish Medical Society Duodecim, Helsinki (2015). Current care guideline: lower respiratory infections [in Finnish with English summary]. www.kaypahoito.fi. Date last updated: January 2 2015. Date last accessed: April 11 2015.
   Google Scholar
• Curtis L, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care. 2007;45:S103–S7.
   PubMed Web of Science ®Google Scholar
• Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf. 2008;17:1202–17.
   PubMed Web of Science ®Google Scholar
• Birks JS. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;CD005593.
   Google Scholar
• Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors. Register-based study of over 700,000 elderly patients. Drugs Aging. 2008;25:871.
   PubMed Web of Science ®Google Scholar
• Taipale H, Tanskanen A, Koponen M, Tolppanen A-M, Tiihonen J, Hartikainen S. Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study. Int Clin Psychopharmacol. 2014;29:216–23.
   PubMed Web of Science ®Google Scholar
• Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. 2011;6:442–65.
   PubMed Web of Science ®Google Scholar
• Rittner HL, Roewer N, Brack A. The clinical (ir)relevance of opioid-induced immune suppression. Curr Opin Anaesthesiol. 2010;23:588–92.
   PubMed Web of Science ®Google Scholar
• Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27:443–54.
   PubMed Web of Science ®Google Scholar
• Masclee GM, Sturkenboom MC, Kuipers EJ. A benefit-risk assessment of the use of proton pump inhibitors in the elderly. Drugs Aging. 2014;31:263–82.
   PubMed Web of Science ®Google Scholar
• Nieto RA, Deardorff WJ, Grossberg GT. Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer’s disease. Expert Opin Pharmacother. 2016;17:861–70.
   PubMed Web of Science ®Google Scholar
• Törmälehto SM, Martikainen JA, Väätäinen ST, Hallikainen IT, Hallikainen M, Bell JS, et al. Use of anti-dementia drugs in relation to change in cognition, behavior, and functioning in Alzheimer’s disease over a three-year period: Kuopio ALSOVA study. J Alzheimers Dis. 2015;48:1033–41.
   PubMed Web of Science ®Google Scholar
• Chouinard J. Dysphagia in Alzheimer disease: a review. J Nutr Health Aging. 2000;4:214–17.
   PubMedGoogle Scholar
• Attems J, König C, Huber M, Lintner F, Jellinger KA. Cause of death in demented and non-demented elderly inpatients; an autopsy study of 308 cases. J Alzheimers Dis. 2005;8:57–62.
   PubMed Web of Science ®Google Scholar
• Kukull WA, Brenner DE, Speck CE, Nochlin D, Bowen J, McCormick W, et al. Causes of death associated with Alzheimer disease: variation by level of cognitive impairment before death. J Am Geriatr Soc. 1994;42:723–6.
   PubMed Web of Science ®Google Scholar
• Wada H, Nakajoh K, Satoh-Nakagawa T, Suzuki T, Ohrui T, Arai H, et al. Risk factors of aspiration pneumonia in Alzheimer’s disease patients. Gerontology. 2001;47:271–6.
   PubMed Web of Science ®Google Scholar
• Mitchell SL, Teno JM, Kiely DK, Shaffer ML, Jones RN, Prigerson HG, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361:1529–38.
   PubMed Web of Science ®Google Scholar
• Ticinesi A, Nouvenne A, Folesani G, Prati B, Morelli I, Guida L, et al. An investigation of multimorbidity measures as risk factors for pneumonia in elderly frail patients admitted to hospital. Eur J Intern Med. 2016;28:102–6.
   PubMed Web of Science ®Google Scholar
• Jarvis B, Figgitt DP. Memantine. Drugs Aging. 2003;20:465–76.
   PubMed Web of Science ®Google Scholar
• Dodler C, Nelson M, McKinsey J. Memantine dosing in patients with dementia. Am J Geriatr Psychiatry. 2009;17:170–3.
   PubMed Web of Science ®Google Scholar
• Tsai YH, Hsieh MJ, Chang CJ, Wen YW, Hu HC, Chao YN, et al. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old–Taiwan’s PPV vaccination program. Vaccine. 2015;33:2897–902.
   PubMed Web of Science ®Google Scholar